{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:53:24Z","timestamp":1781646804872,"version":"3.54.5"},"reference-count":191,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T00:00:00Z","timestamp":1774656000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T00:00:00Z","timestamp":1778112000000},"content-version":"vor","delay-in-days":40,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Manipal Academy of Higher Education, Manipal"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Cisplatin resistance remains a primary obstacle in oncology, leading to therapeutic failure and disease recurrence. While resistance mechanisms are multifactorial, metabolic reprogramming has emerged as a critical adaptive strategy for cancer cells to evade cisplatin-induced cytotoxicity. This review synthesizes current evidence on how altered metabolism drives cisplatin resistance, with a particular emphasis on the pivotal role of pyruvate dehydrogenase kinases (PDKs). PDKs act as metabolic gatekeepers by inhibiting the pyruvate dehydrogenase complex (PDHC), diverting glucose flux away from mitochondrial oxidation toward glycolysis. This switch supports biomass production, maintains redox homeostasis, and dampens reactive oxygen species (ROS) generation, ultimately promoting cell survival. We detail how each PDK isoform (PDK1-4) contributes to resistance through distinct mechanisms, including the regulation of the DNA damage response, cancer stemness, and hypoxia signaling. Furthermore, we discuss the metabolic cues that regulate PDK activity and the role of tumor immune metabolism in cisplatin resistance. Furthermore, we discuss the metabolic cues that regulate PDK activity and the emerging role of tumor immunometabolism in the development of cisplatin resistance. Finally, we highlight the therapeutic potential of targeting PDKs, particularly through pharmacological inhibitors such as dichloroacetate (DCA), while also considering the current challenges associated with PDK-directed therapies. Overall, targeting PDK-mediated metabolic plasticity may offer a promising strategy to overcome cisplatin resistance and improve therapeutic outcomes.<\/jats:p>","DOI":"10.1186\/s12964-026-02845-9","type":"journal-article","created":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T14:04:41Z","timestamp":1774706681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Metabolic reprogramming and cisplatin resistance: the emerging role of Pyruvate Dehydrogenase Kinases (PDKs)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-3009-049X","authenticated-orcid":false,"given":"Aishath","family":"Shaheeda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-3893","authenticated-orcid":false,"given":"Shama Prasada","family":"Kabekkodu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,28]]},"reference":[{"issue":"3","key":"2845_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363. https:\/\/doi.org\/10.3322\/caac.21834.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2845_CR2","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1586\/17474086.2016.1158096","volume":"9","author":"N Daver","year":"2016","unstructured":"Daver N, Cortes J, Kantarjian H, Ravandi F. Acute myeloid leukemia: advancing clinical trials and promising therapeutics. Expert Rev Hematol. 2016;9(5):433\u201345. https:\/\/doi.org\/10.1586\/17474086.2016.1158096.","journal-title":"Expert Rev Hematol"},{"issue":"6","key":"2845_CR3","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1200\/JCO.2008.19.5362","volume":"27","author":"D Sargent","year":"2009","unstructured":"Sargent D, Sobrero A, Grothey A, O\u2019Connell MJ, Buyse M, Andre T, et al. Evidence for cure by adjuvant therapy in colon cancer: observations based on individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2009;27(6):872\u20137. https:\/\/doi.org\/10.1200\/JCO.2008.19.5362.","journal-title":"J Clin Oncol"},{"issue":"11","key":"2845_CR4","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1093\/annonc\/mdx360","volume":"28","author":"M Chovanec","year":"2017","unstructured":"Chovanec M, Abu Zaid M, Hanna N, El-Kouri N, Einhorn LH, Albany C. Long-term toxicity of cisplatin in germ-cell tumor survivors. Ann Oncol. 2017;28(11):2670\u20139. https:\/\/doi.org\/10.1093\/annonc\/mdx360.","journal-title":"Ann Oncol"},{"issue":"9","key":"2845_CR5","doi-asserted-by":"publisher","first-page":"4618","DOI":"10.3390\/ijms22094618","volume":"22","author":"J Jagiela","year":"2021","unstructured":"Jagiela J, Bartnicki P, Rysz J. Nephrotoxicity as a complication of chemotherapy and immunotherapy in the treatment of colorectal cancer, melanoma and non-small cell lung cancer. Int J Mol Sci. 2021;22(9):4618. https:\/\/doi.org\/10.3390\/ijms22094618.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"2845_CR6","doi-asserted-by":"publisher","first-page":"e0298928","DOI":"10.1371\/journal.pone.0298928","volume":"19","author":"JA Wiranata","year":"2024","unstructured":"Wiranata JA, Hutajulu SH, Astari YK, Leo B, Bintoro BS, Hardianti MS, et al. Patient-reported outcomes and symptom clusters pattern of chemotherapy-induced toxicity in patients with early breast cancer. PLoS ONE. 2024;19(2):e0298928. https:\/\/doi.org\/10.1371\/journal.pone.0298928.","journal-title":"PLoS ONE"},{"issue":"1","key":"2845_CR7","doi-asserted-by":"publisher","first-page":"e087302","DOI":"10.1136\/bmjopen-2024-087302","volume":"15","author":"Y Liu","year":"2025","unstructured":"Liu Y, Huang Q, Tian L, Zheng X, Chen G, Xu H, et al. Neoadjuvant adebrelimab combined with chemotherapy (cisplatin\/carboplatin and etoposide) for limited-stage small-cell lung cancer: a study protocol of phase 2 trial (NIUS). BMJ Open. 2025;15(1):e087302. https:\/\/doi.org\/10.1136\/bmjopen-2024-087302.","journal-title":"BMJ Open"},{"key":"2845_CR8","doi-asserted-by":"publisher","first-page":"115323","DOI":"10.1016\/j.bcp.2022.115323","volume":"206","author":"AM Romani","year":"2022","unstructured":"Romani AM. Cisplatin in cancer treatment. Biochem Pharmacol. 2022;206:115323. https:\/\/doi.org\/10.1016\/j.bcp.2022.115323.","journal-title":"Biochem Pharmacol"},{"issue":"47","key":"2845_CR9","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22(47):7265\u201379. https:\/\/doi.org\/10.1038\/sj.onc.1206933.","journal-title":"Oncogene"},{"issue":"1","key":"2845_CR10","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s43556-024-00239-2","volume":"6","author":"Y Gu","year":"2025","unstructured":"Gu Y, Yang R, Zhang Y, Guo M, Takehiro K, Zhan M, et al. Molecular mechanisms and therapeutic strategies in overcoming chemotherapy resistance in cancer. Mol Biomed. 2025;6(1):2. https:\/\/doi.org\/10.1186\/s43556-024-00239-2.","journal-title":"Mol Biomed"},{"issue":"12","key":"2845_CR11","doi-asserted-by":"publisher","first-page":"4158","DOI":"10.1073\/pnas.85.12.4158","volume":"85","author":"JA Rice","year":"1988","unstructured":"Rice JA, Crothers DM, Pinto AL, Lippard SJ. The major adduct of the antitumor drug cis-diamminedichloroplatinum(II) with DNA bends the duplex by approximately 40 degrees toward the major groove. Proc Natl Acad Sci U S A. 1988;85(12):4158\u201361. https:\/\/doi.org\/10.1073\/pnas.85.12.4158.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2845_CR12","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/nrd1691","volume":"4","author":"D Wang","year":"2005","unstructured":"Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4(4):307\u201320. https:\/\/doi.org\/10.1038\/nrd1691.","journal-title":"Nat Rev Drug Discov"},{"key":"2845_CR13","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.3389\/fphys.2018.01898","volume":"9","author":"N Martinho","year":"2019","unstructured":"Martinho N, Santos TCB, Florindo HF, Silva LC. Cisplatin-membrane interactions and their influence on platinum complexes activity and toxicity. Front Physiol. 2019;9:1898. https:\/\/doi.org\/10.3389\/fphys.2018.01898.","journal-title":"Front Physiol"},{"issue":"19","key":"2845_CR14","doi-asserted-by":"publisher","first-page":"5817","DOI":"10.1158\/1078-0432.CCR-06-1037","volume":"12","author":"Z Yang","year":"2006","unstructured":"Yang Z, Schumaker LM, Egorin MJ, Zuhowski EG, Guo Z, Cullen KJ. Cisplatin preferentially binds mitochondrial DNA and voltage-dependent anion channel protein in the mitochondrial membrane of head and neck squamous cell carcinoma: possible role in apoptosis. Clin Cancer Res. 2006;12(19):5817\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-1037.","journal-title":"Clin Cancer Res"},{"issue":"15","key":"2845_CR15","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, et al. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383. https:\/\/doi.org\/10.1038\/onc.2011.384.","journal-title":"Oncogene"},{"issue":"5","key":"2845_CR16","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1124\/mol.62.5.1154","volume":"62","author":"X Lin","year":"2002","unstructured":"Lin X, Okuda T, Holzer A, Howell SB. The copper transporter CTR1 regulates cisplatin uptake in Saccharomyces cerevisiae. Mol Pharmacol. 2002;62(5):1154\u20139. https:\/\/doi.org\/10.1124\/mol.62.5.1154.","journal-title":"Mol Pharmacol"},{"key":"2845_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/1471-2407-8-175","volume":"8","author":"GV Kalayda","year":"2008","unstructured":"Kalayda GV, Wagner CH, Bu\u00df I, Reedijk J, Jaehde U. Altered localization of the copper efflux transporters ATP7A and ATP7B associated with cisplatin resistance in human ovarian carcinoma cells. BMC Cancer. 2008;8:175. https:\/\/doi.org\/10.1186\/1471-2407-8-175.","journal-title":"BMC Cancer"},{"issue":"9","key":"2845_CR18","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1016\/S0006-2952(00)00441-X","volume":"60","author":"KV Ferry","year":"2000","unstructured":"Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol. 2000;60(9):1305\u201313. https:\/\/doi.org\/10.1016\/S0006-2952(00)00441-X.","journal-title":"Biochem Pharmacol"},{"issue":"8","key":"2845_CR19","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.3390\/antiox11081544","volume":"11","author":"D Criscuolo","year":"2022","unstructured":"Criscuolo D, Avolio R, Parri M, Romano S, Chiarugi P, Matassa DS, et al. Decreased levels of GSH are associated with platinum resistance in high-grade serous ovarian cancer. Antioxid (Basel). 2022;11(8):1544. https:\/\/doi.org\/10.3390\/antiox11081544.","journal-title":"Antioxid (Basel)"},{"issue":"5","key":"2845_CR20","doi-asserted-by":"publisher","first-page":"2232","DOI":"10.3390\/ijms26052232","volume":"26","author":"C Madeddu","year":"2025","unstructured":"Madeddu C, Lai E, Neri M, Sanna E, Gramignano G, Nemolato S, et al. Association between TP53 mutations and platinum resistance in a cohort of high-grade serous ovarian cancer patients: novel implications for personalized therapeutics. Int J Mol Sci. 2025;26(5):2232. https:\/\/doi.org\/10.3390\/ijms26052232.","journal-title":"Int J Mol Sci"},{"issue":"36","key":"2845_CR21","doi-asserted-by":"publisher","first-page":"33490","DOI":"10.1074\/jbc.M204042200","volume":"277","author":"S Mabuchi","year":"2002","unstructured":"Mabuchi S, Ohmichi M, Kimura A, Hisamoto K, Hayakawa J, Nishio Y, Adachi K, Takahashi K, Arimoto-Ishida E, Nakatsuji Y, Tasaka K. Inhibition of phosphorylation of BAD and Raf-1 by Akt sensitizes human ovarian cancer cells to paclitaxel. J Biol Chem. 2002;277(36):33490\u2013500. https:\/\/doi.org\/10.1074\/jbc.M204042200.","journal-title":"J Biol Chem"},{"issue":"10","key":"2845_CR22","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.7150\/ijbs.60292","volume":"17","author":"H Yan","year":"2021","unstructured":"Yan H, Luo B, Wu X, Guan F, Yu X, Zhao L, et al. Cisplatin induces pyroptosis via activation of MEG3\/NLRP3\/caspase-1\/GSDMD pathway in triple-negative breast cancer. Int J Biol Sci. 2021;17(10):2606\u201321. https:\/\/doi.org\/10.7150\/ijbs.60292.","journal-title":"Int J Biol Sci"},{"key":"2845_CR23","doi-asserted-by":"publisher","first-page":"102396","DOI":"10.1016\/j.tranon.2025.102396","volume":"56","author":"X Wang","year":"2025","unstructured":"Wang X, Du Q, Mai Q, Zou Q, Wang S, Lin X, et al. Targeting FASN enhances cisplatin sensitivity via SLC7A11-mediated ferroptosis in cervical cancer. Transl Oncol. 2025;56:102396. https:\/\/doi.org\/10.1016\/j.tranon.2025.102396.","journal-title":"Transl Oncol"},{"issue":"5","key":"2845_CR24","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/j.ccell.2025.02.015","volume":"43","author":"Z Yang","year":"2025","unstructured":"Yang Z, Su W, Wei X, Pan Y, Xing M, Niu L, et al. Hypoxia inducible factor-1\u03b1 drives cancer resistance to cuproptosis. Cancer Cell. 2025;43(5):937\u2013e9549. https:\/\/doi.org\/10.1016\/j.ccell.2025.02.015.","journal-title":"Cancer Cell"},{"issue":"6487","key":"2845_CR25","doi-asserted-by":"publisher","first-page":"eaaw5473","DOI":"10.1126\/science.aaw5473","volume":"368","author":"B Faubert","year":"2020","unstructured":"Faubert B, Solmonson A, DeBerardinis RJ. Metabolic reprogramming and cancer progression. Science. 2020;368(6487):eaaw5473. https:\/\/doi.org\/10.1126\/science.aaw5473.","journal-title":"Science"},{"issue":"3191","key":"2845_CR26","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309\u201314. https:\/\/doi.org\/10.1126\/science.123.3191.309.","journal-title":"Science"},{"issue":"1","key":"2845_CR27","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","volume":"29","author":"G Gentric","year":"2019","unstructured":"Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al. PML-regulated mitochondrial metabolism enhances chemosensitivity in human ovarian cancers. Cell Metab. 2019;29(1):156\u2013e17310. https:\/\/doi.org\/10.1016\/j.cmet.2018.09.002.","journal-title":"Cell Metab"},{"issue":"1","key":"2845_CR28","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/s41419-024-06435-w","volume":"15","author":"J Chen","year":"2024","unstructured":"Chen J, Cui L, Lu S, Xu S. Amino acid metabolism in tumor biology and therapy. Cell Death Dis. 2024;15(1):42. https:\/\/doi.org\/10.1038\/s41419-024-06435-w.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2845_CR29","doi-asserted-by":"publisher","first-page":"4554","DOI":"10.1038\/s41467-022-32101-w","volume":"13","author":"Y Tan","year":"2022","unstructured":"Tan Y, Li J, Zhao G, Huang KC, Cardenas H, Wang Y, et al. Metabolic reprogramming from glycolysis to fatty acid uptake and beta-oxidation in platinum-resistant cancer cells. Nat Commun. 2022;13(1):4554. https:\/\/doi.org\/10.1038\/s41467-022-32101-w.","journal-title":"Nat Commun"},{"issue":"17","key":"2845_CR30","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.3390\/cancers16173082","volume":"16","author":"NV Pervushin","year":"2024","unstructured":"Pervushin NV, Yapryntseva MA, Panteleev MA, Zhivotovsky B, Kopeina GS. Cisplatin resistance and metabolism: simplification of complexity. Cancers (Basel). 2024;16(17):3082. https:\/\/doi.org\/10.3390\/cancers16173082.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2845_CR31","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1038\/s41598-017-09206-0","volume":"7","author":"S Dar","year":"2017","unstructured":"Dar S, Chhina J, Mert I, Chitale D, Buekers T, Kaur H, et al. Bioenergetic adaptations in chemoresistant ovarian cancer cells. Sci Rep. 2017;7(1):8760. https:\/\/doi.org\/10.1038\/s41598-017-09206-0.","journal-title":"Sci Rep"},{"issue":"3","key":"2845_CR32","doi-asserted-by":"publisher","first-page":"937","DOI":"10.3390\/ijms21030937","volume":"21","author":"I Giacomini","year":"2020","unstructured":"Giacomini I, Ragazzi E, Pasut G, Montopoli M. The pentose phosphate pathway and its involvement in cisplatin resistance. Int J Mol Sci. 2020;21(3):937. https:\/\/doi.org\/10.3390\/ijms21030937.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"2845_CR33","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1080\/1061186X.2018.1550648","volume":"27","author":"T Hu","year":"2019","unstructured":"Hu T, Yu S, Li Y, Ren H, Ning Q, Wang J, et al. PDK2 induces cisplatin resistance in lung adenocarcinoma via transcriptional regulation of CNNM3. J Drug Target. 2019;27(4):460\u20135. https:\/\/doi.org\/10.1080\/1061186X.2018.1550648.","journal-title":"J Drug Target"},{"issue":"3","key":"2845_CR34","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11060-023-04521-1","volume":"165","author":"BB Yavuz","year":"2023","unstructured":"Yavuz BB, Kilinc F, Kanyilmaz G, Aktan M. Pyruvate kinase M2 (PKM2) expression and prognostic significance in glioblastoma patients. J Neurooncol. 2023;165(3):527\u201333. https:\/\/doi.org\/10.1007\/s11060-023-04521-1.","journal-title":"J Neurooncol"},{"issue":"8","key":"2845_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41419-023-06050-1","volume":"14","author":"C Yang","year":"2023","unstructured":"Yang C, Ou Y, Zhou Q, Liang Y, Li W, Chen Y, et al. Methionine orchestrates the metabolism vulnerability in cisplatin resistant bladder cancer microenvironment. Cell Death Dis. 2023;14(8):525. https:\/\/doi.org\/10.1038\/s41419-023-06050-1.","journal-title":"Cell Death Dis"},{"issue":"24","key":"2845_CR36","doi-asserted-by":"publisher","first-page":"7277","DOI":"10.1158\/0008-5472.CAN-13-1868","volume":"73","author":"KK Velpula","year":"2013","unstructured":"Velpula KK, Bhasin A, Asuthkar S, Tsung AJ. Combined targeting of PDK1 and EGFR triggers regression of glioblastoma by reversing the Warburg effect. Cancer Res. 2013;73(24):7277\u201389. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1868.","journal-title":"Cancer Res"},{"issue":"4","key":"2845_CR37","doi-asserted-by":"publisher","first-page":"BSR20204402","DOI":"10.1042\/BSR20204402","volume":"41","author":"X Wang","year":"2021","unstructured":"Wang X, Shen X, Yan Y, Li H. Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications. Biosci Rep. 2021;41(4):BSR20204402. https:\/\/doi.org\/10.1042\/BSR20204402.","journal-title":"Biosci Rep"},{"issue":"7","key":"2845_CR38","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.bjc.6604554","volume":"99","author":"ED Michelakis","year":"2008","unstructured":"Michelakis ED, Webster L, Mackey JR. Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer. 2008;99(7):989\u201394. https:\/\/doi.org\/10.1038\/sj.bjc.6604554.","journal-title":"Br J Cancer"},{"issue":"3","key":"2845_CR39","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s10637-015-0221-y","volume":"33","author":"QSC Chu","year":"2015","unstructured":"Chu QSC, Sangha R, Spratlin J, Vos LJ, Mackey JR, McEwan AJB, et al. A phase I open-label, single-arm, dose-escalation study of dichloroacetate (DCA) in patients with advanced solid tumors. Invest New Drugs. 2015;33(3):603\u201310. https:\/\/doi.org\/10.1007\/s10637-015-0221-y.","journal-title":"Invest New Drugs"},{"issue":"3","key":"2845_CR40","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.cmet.2022.01.007","volume":"34","author":"NN Pavlova","year":"2022","unstructured":"Pavlova NN, Zhu J, Thompson CB. The hallmarks of cancer metabolism: still emerging. Cell Metab. 2022;34(3):355\u201377. https:\/\/doi.org\/10.1016\/j.cmet.2022.01.007.","journal-title":"Cell Metab"},{"issue":"1","key":"2845_CR41","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s42003-024-07284-1","volume":"8","author":"Y Gong","year":"2025","unstructured":"Gong Y, Gao D, Shi Y, Fan G, Yu X, Yang E, et al. SRC enhanced cisplatin resistance in bladder cancer by reprogramming glycolysis and pentose phosphate pathway. Commun Biol. 2025;8(1):36. https:\/\/doi.org\/10.1038\/s42003-024-07284-1.","journal-title":"Commun Biol"},{"issue":"30","key":"2845_CR42","doi-asserted-by":"publisher","first-page":"30102","DOI":"10.18632\/oncotarget.4945","volume":"6","author":"D Catanzaro","year":"2015","unstructured":"Catanzaro D, Gaude E, Orso G, Giordano C, Guzzo G, Rasola A, et al. Inhibition of glucose-6-phosphate dehydrogenase sensitizes cisplatin-resistant cells to death. Oncotarget. 2015;6(30):30102\u201314. https:\/\/doi.org\/10.18632\/oncotarget.4945.","journal-title":"Oncotarget"},{"issue":"4","key":"2845_CR43","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.ajog.2009.10.883","volume":"202","author":"P Loar","year":"2010","unstructured":"Loar P, Wahl H, Kshirsagar M, Gossner G, Griffith K, Liu JR. Inhibition of glycolysis enhances cisplatin-induced apoptosis in ovarian cancer cells. Am J Obstet Gynecol. 2010;202(4):371. .e1-371.e8.","journal-title":"Am J Obstet Gynecol"},{"issue":"8","key":"2845_CR44","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","volume":"11","author":"Y Liu","year":"2012","unstructured":"Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H, et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Ther. 2012;11(8):1672\u201382. https:\/\/doi.org\/10.1158\/1535-7163.MCT-12-0131.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2845_CR45","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1159\/000354466","volume":"32","author":"S Li","year":"2013","unstructured":"Li S, Yang X, Wang P, Ran X. The effects of GLUT1 on the survival of head and neck squamous cell carcinoma. Cell Physiol Biochem. 2013;32(3):624\u201334. https:\/\/doi.org\/10.1159\/000354466.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"2845_CR46","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1111\/cas.13995","volume":"110","author":"H Sawayama","year":"2019","unstructured":"Sawayama H, Ogata Y, Ishimoto T, Mima K, Hiyoshi Y, Iwatsuki M, et al. Glucose transporter 1 regulates the proliferation and cisplatin sensitivity of esophageal cancer. Cancer Sci. 2019;110(5):1705\u201314. https:\/\/doi.org\/10.1111\/cas.13995.","journal-title":"Cancer Sci"},{"key":"2845_CR47","doi-asserted-by":"publisher","first-page":"105688","DOI":"10.1016\/j.archoralbio.2023.105688","volume":"150","author":"A Kumari","year":"2023","unstructured":"Kumari A, Jha A, Tiwari A, Nath N, Kumar A, Nagini S, et al. Role and regulation of GLUT1\/3 during oral cancer progression and therapy resistance. Arch Oral Biol. 2023;150:105688. https:\/\/doi.org\/10.1016\/j.archoralbio.2023.105688.","journal-title":"Arch Oral Biol"},{"key":"2845_CR48","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.biocel.2017.12.010","volume":"95","author":"XY Zhang","year":"2018","unstructured":"Zhang XY, Zhang M, Cong Q, Zhang MX, Zhang MY, Lu YY, et al. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol. 2018;95:9\u201316. https:\/\/doi.org\/10.1016\/j.biocel.2017.12.010.","journal-title":"Int J Biochem Cell Biol"},{"issue":"2","key":"2845_CR49","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3233\/CBM-191181","volume":"28","author":"JF Wen","year":"2020","unstructured":"Wen JF, Jiang YQ, Li C, Dai XK, Wu T, Yin WZ. LncRNA-SARCC sensitizes osteosarcoma to cisplatin through the miR-143-mediated glycolysis inhibition by targeting hexokinase 2. Cancer Biomark. 2020;28(2):231\u201346. https:\/\/doi.org\/10.3233\/CBM-191181.","journal-title":"Cancer Biomark"},{"issue":"19","key":"2845_CR50","doi-asserted-by":"publisher","first-page":"13482","DOI":"10.1074\/jbc.M708216200","volume":"283","author":"S Abu-Hamad","year":"2008","unstructured":"Abu-Hamad S, Zaid H, Israelson A, Nahon E, Shoshan-Barmatz V. Hexokinase-I protection against apoptotic cell death is mediated via interaction with the voltage-dependent anion channel-1: mapping the site of binding. J Biol Chem. 2008;283(19):13482\u201390. https:\/\/doi.org\/10.1074\/jbc.M708216200.","journal-title":"J Biol Chem"},{"key":"2845_CR51","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/s41467-018-02950-5","volume":"9","author":"FL Li","year":"2018","unstructured":"Li FL, Liu JP, Bao RX, Yan G, Feng X, Xu YP, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun. 2018;9:508. https:\/\/doi.org\/10.1038\/s41467-018-02950-5.","journal-title":"Nat Commun"},{"issue":"6","key":"2845_CR52","doi-asserted-by":"publisher","first-page":"968","DOI":"10.1016\/j.ccell.2016.10.006","volume":"30","author":"AR Cantelmo","year":"2016","unstructured":"Cantelmo AR, Conradi LC, Brajic A, Goveia J, Kalucka J, Pircher A, et al. Inhibition of the glycolytic activator PFKFB3 in endothelium induces tumor vessel normalization, impairs metastasis, and improves chemotherapy. Cancer Cell. 2016;30(6):968\u201385. https:\/\/doi.org\/10.1016\/j.ccell.2016.10.006.","journal-title":"Cancer Cell"},{"issue":"29","key":"2845_CR53","doi-asserted-by":"publisher","first-page":"47691","DOI":"10.18632\/oncotarget.17868","volume":"8","author":"X Qian","year":"2017","unstructured":"Qian X, Xu W, Xu J, Shi Q, Li J, Weng Y, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. Oncotarget. 2017;8(29):47691\u2013708. https:\/\/doi.org\/10.18632\/oncotarget.17868.","journal-title":"Oncotarget"},{"issue":"7184","key":"2845_CR54","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/nature06734","volume":"452","author":"HR Christofk","year":"2008","unstructured":"Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R, et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumor growth. Nature. 2008;452(7184):230\u20133. https:\/\/doi.org\/10.1038\/nature06734.","journal-title":"Nature"},{"issue":"9","key":"2845_CR55","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/bjc.2014.492","volume":"111","author":"C Papadaki","year":"2014","unstructured":"Papadaki C, Sfakianaki M, Lagoudaki E, Giagkas G, Ioannidis G, Trypaki M, et al. PKM2 as a biomarker for chemosensitivity to front-line platinum-based chemotherapy in patients with metastatic non-small cell lung cancer. Br J Cancer. 2014;111(9):1757\u201364. https:\/\/doi.org\/10.1038\/bjc.2014.492.","journal-title":"Br J Cancer"},{"issue":"1","key":"2845_CR56","doi-asserted-by":"publisher","first-page":"14626","DOI":"10.1038\/s41598-025-96562-x","volume":"15","author":"H Zheng","year":"2025","unstructured":"Zheng H, Tan J, Qin F, Zheng Y, Yang X, Liu Z, et al. PKM2 modulates chemotherapy sensitivity by regulating autophagy and predicts the prognosis and immunity in pancancer. Sci Rep. 2025;15(1):14626. https:\/\/doi.org\/10.1038\/s41598-025-96562-x.","journal-title":"Sci Rep"},{"issue":"1","key":"2845_CR57","doi-asserted-by":"publisher","first-page":"45983","DOI":"10.1038\/srep45983","volume":"7","author":"X Wang","year":"2017","unstructured":"Wang X, Zhang F, Wu XR. Inhibition of pyruvate kinase M2 markedly reduces chemoresistance of advanced bladder cancer to cisplatin. Sci Rep. 2017;7(1):45983. https:\/\/doi.org\/10.1038\/srep45983.","journal-title":"Sci Rep"},{"issue":"6","key":"2845_CR58","doi-asserted-by":"publisher","first-page":"2860","DOI":"10.7150\/thno.51797","volume":"11","author":"D Wang","year":"2021","unstructured":"Wang D, Zhao C, Xu F, Zhang A, Jin M, Zhang K, et al. Cisplatin-resistant NSCLC cells induced by hypoxia transmit resistance to sensitive cells through exosomal PKM2. Theranostics. 2021;11(6):2860\u201375. https:\/\/doi.org\/10.7150\/thno.51797.","journal-title":"Theranostics"},{"issue":"1","key":"2845_CR59","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41419-025-07431-4","volume":"16","author":"R He","year":"2025","unstructured":"He R, Hu C, Yuan Y, Li T, Tian Q, Huang T, et al. Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4-mediated PKM2 nuclear translocation. Cell Death Dis. 2025;16(1):126. https:\/\/doi.org\/10.1038\/s41419-025-07431-4.","journal-title":"Cell Death Dis"},{"key":"2845_CR60","doi-asserted-by":"publisher","first-page":"1609951","DOI":"10.3389\/pore.2021.1609951","volume":"27","author":"M Govoni","year":"2021","unstructured":"Govoni M, Rossi V, Di Stefano G, Manerba M. Lactate upregulates the expression of DNA repair genes, causing intrinsic resistance of cancer cells to cisplatin. Pathol Oncol Res. 2021;27:1609951. https:\/\/doi.org\/10.3389\/pore.2021.1609951.","journal-title":"Pathol Oncol Res"},{"key":"2845_CR61","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ejps.2015.04.022","volume":"74","author":"M Manerba","year":"2015","unstructured":"Manerba M, Di Ianni L, Fiume L, Roberti M, Recanatini M, Di Stefano G. Lactate dehydrogenase inhibitors sensitize lymphoma cells to cisplatin without enhancing the drug effects on immortalized normal lymphocytes. Eur J Pharm Sci. 2015;74:95\u2013102. https:\/\/doi.org\/10.1016\/j.ejps.2015.04.022.","journal-title":"Eur J Pharm Sci"},{"issue":"1","key":"2845_CR62","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41389-025-00571-4","volume":"14","author":"Y Lin","year":"2025","unstructured":"Lin Y, Dubey C, Losmanova T, Yasmin SO, Reymond JL, Peng RW, et al. Inhibition of LDHB triggers DNA damage and increases cisplatin sensitivity in pleural mesothelioma. Oncogenesis. 2025;14(1):28. https:\/\/doi.org\/10.1038\/s41389-025-00571-4.","journal-title":"Oncogenesis"},{"issue":"15","key":"2845_CR63","doi-asserted-by":"publisher","first-page":"12397","DOI":"10.3390\/ijms241512397","volume":"24","author":"J Chun","year":"2023","unstructured":"Chun J. Isoalantolactone suppresses glycolysis and resensitizes cisplatin-based chemotherapy in cisplatin-resistant ovarian cancer cells. Int J Mol Sci. 2023;24(15):12397. https:\/\/doi.org\/10.3390\/ijms241512397.","journal-title":"Int J Mol Sci"},{"key":"2845_CR64","doi-asserted-by":"publisher","first-page":"691795","DOI":"10.3389\/fmolb.2021.691795","volume":"8","author":"L Wang","year":"2021","unstructured":"Wang L, Zhao X, Fu J, Xu W, Yuan J. The role of tumor metabolism in cisplatin resistance. Front Mol Biosci. 2021;8:691795. https:\/\/doi.org\/10.3389\/fmolb.2021.691795.","journal-title":"Front Mol Biosci"},{"issue":"7","key":"2845_CR65","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.3390\/cancers16071418","volume":"16","author":"J Afonso","year":"2024","unstructured":"Afonso J, Barbosa-Matos C, Silvestre R, Pereira-Vieira J, Gon\u00e7alves SM, Mendes-Alves C, et al. Cisplatin-resistant urothelial bladder cancer cells undergo metabolic reprogramming beyond the Warburg effect. Cancers (Basel). 2024;16(7):1418. https:\/\/doi.org\/10.3390\/cancers16071418.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2845_CR66","doi-asserted-by":"publisher","first-page":"62","DOI":"10.3390\/cancers15010062","volume":"15","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Mei Y, Wang Z, He W. The effect of oxidative phosphorylation on cancer drug resistance. Cancers (Basel). 2022;15(1):62. https:\/\/doi.org\/10.3390\/cancers15010062.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2845_CR67","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1016\/j.ajpath.2011.05.050","volume":"179","author":"CW Lu","year":"2011","unstructured":"Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW, Lee JC, Tsai SJ. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol. 2011;179(3):1405\u201314. https:\/\/doi.org\/10.1016\/j.ajpath.2011.05.050.","journal-title":"Am J Pathol"},{"issue":"14","key":"2845_CR68","doi-asserted-by":"publisher","first-page":"5057","DOI":"10.7150\/thno.84937","volume":"13","author":"J Deng","year":"2023","unstructured":"Deng J, Pan T, Lv C, Cao L, Li L, Zhou X, et al. Exosomal transfer leads to chemoresistance through oxidative phosphorylation-mediated stemness phenotype in colorectal cancer. Theranostics. 2023;13(14):5057\u201374. https:\/\/doi.org\/10.7150\/thno.84937.","journal-title":"Theranostics"},{"issue":"6","key":"2845_CR69","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1016\/j.bbabio.2010.10.012","volume":"1807","author":"C Jose","year":"2011","unstructured":"Jose C, Bellance N, Rossignol R. Choosing between glycolysis and oxidative phosphorylation: a tumor\u2019s dilemma? Biochim Biophys Acta Bioenerg. 2011;1807(6):552\u201361. https:\/\/doi.org\/10.1016\/j.bbabio.2010.10.012.","journal-title":"Biochim Biophys Acta Bioenerg"},{"issue":"8","key":"2845_CR70","doi-asserted-by":"publisher","first-page":"2446","DOI":"10.1007\/s12015-025-10956-y","volume":"21","author":"LQ Keoh","year":"2025","unstructured":"Keoh LQ, Chiu CF, Ramasamy TS. Metabolic plasticity and cancer stem cell metabolism: exploring the glycolysis-OXPHOS switch as a mechanism for resistance and tumorigenesis. Stem Cell Rev Rep. 2025;21(8):2446\u201368. https:\/\/doi.org\/10.1007\/s12015-025-10956-y.","journal-title":"Stem Cell Rev Rep"},{"issue":"1","key":"2845_CR71","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.canlet.2016.01.009","volume":"373","author":"Z Ai","year":"2016","unstructured":"Ai Z, Lu Y, Qiu S, Fan Z. Overcoming cisplatin resistance of ovarian cancer cells by targeting HIF-1-regulated cancer metabolism. Cancer Lett. 2016;373(1):36\u201344. https:\/\/doi.org\/10.1016\/j.canlet.2016.01.009.","journal-title":"Cancer Lett"},{"issue":"1","key":"2845_CR72","doi-asserted-by":"publisher","first-page":"5518","DOI":"10.1038\/s41598-022-09438-9","volume":"12","author":"T Xu","year":"2022","unstructured":"Xu T, Junge JA, Delfarah A, Lu YT, Arnesano C, Iqbal M, et al. Bladder cancer cells shift rapidly and spontaneously to cisplatin-resistant oxidative phosphorylation that is trackable in real time. Sci Rep. 2022;12(1):5518. https:\/\/doi.org\/10.1038\/s41598-022-09438-9.","journal-title":"Sci Rep"},{"key":"2845_CR73","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1186\/s12967-022-03447-y","volume":"20","author":"S Sriramkumar","year":"2022","unstructured":"Sriramkumar S, Sood R, Huntington TD, Ghobashi AH, Vuong TT, Metcalfe TX, et al. Platinum-induced mitochondrial OXPHOS contributes to cancer stem cell enrichment in ovarian cancer. J Transl Med. 2022;20:246. https:\/\/doi.org\/10.1186\/s12967-022-03447-y.","journal-title":"J Transl Med"},{"issue":"1","key":"2845_CR74","doi-asserted-by":"publisher","first-page":"12223","DOI":"10.1038\/s41598-017-09426-4","volume":"7","author":"MV Shirmanova","year":"2017","unstructured":"Shirmanova MV, Druzhkova IN, Lukina MM, Dudenkova VV, Ignatova NI, Snopova LB, et al. Chemotherapy with cisplatin: insights into intracellular pH and metabolic landscape of cancer cells in vitro and in vivo. Sci Rep. 2017;7(1):12223. https:\/\/doi.org\/10.1038\/s41598-017-09426-4.","journal-title":"Sci Rep"},{"issue":"1","key":"2845_CR75","doi-asserted-by":"publisher","first-page":"4537","DOI":"10.1038\/s41598-017-04626-4","volume":"7","author":"JG Ren","year":"2017","unstructured":"Ren JG, Seth P, Ye H, Guo K, Hanai JI, Husain Z, et al. Citrate suppresses tumor growth in multiple models through inhibition of glycolysis, the tricarboxylic acid cycle and the IGF-1R pathway. Sci Rep. 2017;7(1):4537. https:\/\/doi.org\/10.1038\/s41598-017-04626-4.","journal-title":"Sci Rep"},{"key":"2845_CR76","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jare.2024.04.033","volume":"65","author":"Y Wu","year":"2024","unstructured":"Wu Y, Jia C, Liu W, Zhan W, Chen Y, Lu J, et al. Sodium citrate targeting Ca2+\/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer. J Adv Res. 2024;65:89\u2013104. https:\/\/doi.org\/10.1016\/j.jare.2024.04.033.","journal-title":"J Adv Res"},{"issue":"2","key":"2845_CR77","doi-asserted-by":"publisher","first-page":"475","DOI":"10.3390\/biomedicines11020475","volume":"11","author":"H Li","year":"2023","unstructured":"Li H, Li J, Lu W, Yang J, Xia Y, Huang P. Targeting mitochondrial IDH2 enhances antitumor activity of cisplatin in lung cancer via ROS-mediated mechanism. Biomedicines. 2023;11(2):475. https:\/\/doi.org\/10.3390\/biomedicines11020475.","journal-title":"Biomedicines"},{"key":"2845_CR78","doi-asserted-by":"publisher","first-page":"114202","DOI":"10.1016\/j.bcp.2020.114202","volume":"180","author":"F Ciccarone","year":"2020","unstructured":"Ciccarone F, De Falco P, Ciriolo MR. Aconitase 2 sensitizes MCF-7 cells to cisplatin eliciting p53-mediated apoptosis in a ROS-dependent manner. Biochem Pharmacol. 2020;180:114202. https:\/\/doi.org\/10.1016\/j.bcp.2020.114202.","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"2845_CR79","doi-asserted-by":"publisher","first-page":"3759","DOI":"10.3390\/ijms21113759","volume":"21","author":"VI Bunik","year":"2020","unstructured":"Bunik VI, Aleshin VA, Zhou X, Tabakov VY, Karlsson A. Activation of mitochondrial 2-oxoglutarate dehydrogenase by cocarboxylase in human lung adenocarcinoma cells A549 is p53\/p21-dependent and impairs cellular redox state, mimicking the cisplatin action. Int J Mol Sci. 2020;21(11):3759. https:\/\/doi.org\/10.3390\/ijms21113759.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2845_CR80","doi-asserted-by":"publisher","first-page":"9820","DOI":"10.1038\/s41467-024-53398-9","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, Xian M, Ying W, Liu J, Bing S, Wang X, et al. Succinate dehydrogenase deficiency-driven succinate accumulation induces drug resistance in acute myeloid leukemia via ubiquitin-cullin regulation. Nat Commun. 2024;15(1):9820. https:\/\/doi.org\/10.1038\/s41467-024-53398-9.","journal-title":"Nat Commun"},{"issue":"1","key":"2845_CR81","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.ccr.2004.11.022","volume":"7","author":"MA Selak","year":"2005","unstructured":"Selak MA, Armour SM, MacKenzie ED, Boulahbel H, Watson DG, Mansfield KD, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. Cancer Cell. 2005;7(1):77\u201385. https:\/\/doi.org\/10.1016\/j.ccr.2004.11.022.","journal-title":"Cancer Cell"},{"issue":"664","key":"2845_CR82","doi-asserted-by":"publisher","first-page":"eabc4436","DOI":"10.1126\/scisignal.abc4436","volume":"14","author":"DR Crooks","year":"2021","unstructured":"Crooks DR, Maio N, Lang M, Ricketts CJ, Vocke CD, Gurram S, et al. Mitochondrial DNA alterations underlie an irreversible shift to aerobic glycolysis in fumarate hydratase-deficient renal cancer. Sci Signal. 2021;14(664):eabc4436. https:\/\/doi.org\/10.1126\/scisignal.abc4436.","journal-title":"Sci Signal"},{"issue":"8","key":"2845_CR83","doi-asserted-by":"publisher","first-page":"eabf9096","DOI":"10.1126\/sciadv.abf9096","volume":"8","author":"J Whitburn","year":"2022","unstructured":"Whitburn J, Rao SR, Morris EV, Tabata S, Hirayama A, Soga T, et al. Metabolic profiling of prostate cancer in skeletal microenvironments identifies G6PD as a key mediator of growth and survival. Sci Adv. 2022;8(8):eabf9096. https:\/\/doi.org\/10.1126\/sciadv.abf9096.","journal-title":"Sci Adv"},{"issue":"1","key":"2845_CR84","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.1038\/s41467-020-15308-7","volume":"11","author":"Q Li","year":"2020","unstructured":"Li Q, Qin T, Bi Z, Hong H, Ding L, Chen J, et al. Rac1 activates nonoxidative pentose phosphate pathway to induce chemoresistance of breast cancer. Nat Commun. 2020;11(1):1456. https:\/\/doi.org\/10.1038\/s41467-020-15308-7.","journal-title":"Nat Commun"},{"issue":"1","key":"2845_CR85","doi-asserted-by":"publisher","first-page":"115142","DOI":"10.1016\/j.celrep.2024.115142","volume":"44","author":"M Fu","year":"2025","unstructured":"Fu M, Zhang M, Zhang L, Feng Y, Gao C, Xu H, Zhang J, Zhang H, Peng T, Chu Y, Wu Y. Transketolase attenuates the chemotherapy sensitivity of glioma cells by modulating R-loop formation. Cell Rep. 2025;44(1):115142. https:\/\/doi.org\/10.1016\/j.celrep.2024.115142.","journal-title":"Cell Rep"},{"key":"2845_CR86","doi-asserted-by":"publisher","first-page":"783194","DOI":"10.3389\/fonc.2021.783194","volume":"11","author":"H Yang","year":"2021","unstructured":"Yang H, Zhang MZ, Sun HW, Chai YT, Li X, Jiang Q, et al. A novel microcrystalline BAY-876 formulation achieves long-acting antitumor activity against aerobic glycolysis and proliferation of hepatocellular carcinoma. Front Oncol. 2021;11:783194. https:\/\/doi.org\/10.3389\/fonc.2021.783194.","journal-title":"Front Oncol"},{"issue":"2","key":"2845_CR87","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00280-012-2045-1","volume":"71","author":"LE Raez","year":"2013","unstructured":"Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, DiPaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523\u201330. https:\/\/doi.org\/10.1007\/s00280-012-2045-1.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"8","key":"2845_CR88","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29(8):1429\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2263.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2845_CR89","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/s11523-013-0273-x","volume":"8","author":"S Ota","year":"2013","unstructured":"Ota S, Geschwind JFH, Buijs M, Wijlemans JW, Kwak BK, Ganapathy-Kanniappan S. Ultrasound-guided direct delivery of 3-bromopyruvate blocks tumor progression in an orthotopic mouse model of human pancreatic cancer. Target Oncol. 2013;8(2):145\u201351. https:\/\/doi.org\/10.1007\/s11523-013-0273-x.","journal-title":"Target Oncol"},{"issue":"1","key":"2845_CR90","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.acra.2006.09.059","volume":"14","author":"JM Chang","year":"2007","unstructured":"Chang JM, Chung JW, Jae HJ, Eh H, Son KR, Lee KC, et al. Local toxicity of hepatic arterial infusion of hexokinase II inhibitor, 3-bromopyruvate: in vivo investigation in normal rabbit model. Acad Radiol. 2007;14(1):85\u201392. https:\/\/doi.org\/10.1016\/j.acra.2006.09.059.","journal-title":"Acad Radiol"},{"issue":"12","key":"2845_CR91","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.3390\/cancers17122034","volume":"17","author":"C Tarantelli","year":"2025","unstructured":"Tarantelli C, Spriano F, Civanelli E, Aresu L, Risi G, Cannas E, et al. KAT\/3BP: a metabolism-targeting agent with single and combination activity in aggressive B-cell lymphomas. Cancers (Basel). 2025;17(12):2034. https:\/\/doi.org\/10.3390\/cancers17122034.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"2845_CR92","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s00280-019-03886-3","volume":"84","author":"S Pintova","year":"2019","unstructured":"Pintova S, Dharmupari S, Moshier E, Zubizarreta N, Ang C, Holcombe RF. Genistein combined with FOLFOX or FOLFOX-bevacizumab for the treatment of metastatic colorectal cancer: phase I\/II pilot study. Cancer Chemother Pharmacol. 2019;84(3):591\u20138. https:\/\/doi.org\/10.1007\/s00280-019-03886-3.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"2","key":"2845_CR93","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.canlet.2006.10.013","volume":"250","author":"A Heyfets","year":"2007","unstructured":"Heyfets A, Flescher E. Cooperative cytotoxicity of methyl jasmonate with anticancer drugs and 2-deoxy-D-glucose. Cancer Lett. 2007;250(2):300\u201310. https:\/\/doi.org\/10.1016\/j.canlet.2006.10.013.","journal-title":"Cancer Lett"},{"key":"2845_CR94","doi-asserted-by":"publisher","first-page":"153805","DOI":"10.1016\/j.phymed.2021.153805","volume":"94","author":"Q Sun","year":"2022","unstructured":"Sun Q, Gong T, Liu M, Ren S, Yang H, Zeng S, et al. Shikonin, a naphthalene ingredient: therapeutic actions, pharmacokinetics, toxicology, clinical trials and pharmaceutical studies. Phytomedicine. 2022;94:153805. https:\/\/doi.org\/10.1016\/j.phymed.2021.153805.","journal-title":"Phytomedicine"},{"key":"2845_CR95","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41418-025-01532-5","volume":"32","author":"J Dreute","year":"2025","unstructured":"Dreute J, Stengel J, Becher J, van den Borre D, Pfisterer M, Bartkuhn M, et al. Synergistic targeting of cancer cells through simultaneous inhibition of key metabolic enzymes. Cell Death Differ. 2025;32:1\u201318. https:\/\/doi.org\/10.1038\/s41418-025-01532-5.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2845_CR96","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10637-023-01416-w","volume":"42","author":"JC Huynh","year":"2024","unstructured":"Huynh JC, Cho M, Monjazeb A, Al-Obeidi E, Singh A, Tam K, et al. Phase I\/II trial of BMS-986205 and nivolumab as first-line therapy in hepatocellular carcinoma. Invest New Drugs. 2024;42(1):35\u201343. https:\/\/doi.org\/10.1007\/s10637-023-01416-w.","journal-title":"Invest New Drugs"},{"issue":"19","key":"2845_CR97","doi-asserted-by":"publisher","first-page":"5060","DOI":"10.1158\/0008-5472.CAN-19-0217","volume":"79","author":"C Yeung","year":"2019","unstructured":"Yeung C, Gibson AE, Issaq SH, Oshima N, Baumgart JT, Edessa LD, et al. Targeting glycolysis through inhibition of lactate dehydrogenase impairs tumor growth in preclinical models of Ewing sarcoma. Cancer Res. 2019;79(19):5060\u201373. https:\/\/doi.org\/10.1158\/0008-5472.CAN-19-0217.","journal-title":"Cancer Res"},{"issue":"9","key":"2845_CR98","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1038\/cdd.2016.39","volume":"23","author":"DS Matassa","year":"2016","unstructured":"Matassa DS, Amoroso MR, Lu H, Avolio R, Arzeni D, Procaccini C, et al. Oxidative metabolism drives inflammation-induced platinum resistance in human ovarian cancer. Cell Death Differ. 2016;23(9):1542\u201354. https:\/\/doi.org\/10.1038\/cdd.2016.39.","journal-title":"Cell Death Differ"},{"issue":"1","key":"2845_CR99","doi-asserted-by":"publisher","first-page":"4067","DOI":"10.1038\/s41598-018-21831-x","volume":"8","author":"G Duan","year":"2018","unstructured":"Duan G, Shi M, Xie L, Xu M, Wang Y, Yan H, et al. Increased glutamine consumption in cisplatin-resistant cells has a negative impact on cell growth. Sci Rep. 2018;8(1):4067. https:\/\/doi.org\/10.1038\/s41598-018-21831-x.","journal-title":"Sci Rep"},{"issue":"1","key":"2845_CR100","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1186\/s12885-021-07879-5","volume":"21","author":"J Guo","year":"2021","unstructured":"Guo J, Satoh K, Tabata S, Mori M, Tomita M, Soga T. Reprogramming of glutamine metabolism via glutamine synthetase silencing induces cisplatin resistance in A2780 ovarian cancer cells. BMC Cancer. 2021;21(1):174. https:\/\/doi.org\/10.1186\/s12885-021-07879-5.","journal-title":"BMC Cancer"},{"issue":"1","key":"2845_CR101","doi-asserted-by":"publisher","first-page":"30528","DOI":"10.1038\/s41598-025-15707-0","volume":"15","author":"A Ponton-Almodovar","year":"2025","unstructured":"Ponton-Almodovar A, Udumula MP, Khullar V, Rashid F, Rattan R, Bernard JJ, et al. GPT2 mediates glutamine metabolism-driven metabolic alterations in platinum-resistant ovarian cancer cells. Sci Rep. 2025;15(1):30528. https:\/\/doi.org\/10.1038\/s41598-025-15707-0.","journal-title":"Sci Rep"},{"issue":"5","key":"2845_CR102","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1016\/j.advnut.2023.05.007","volume":"14","author":"W Shunxi","year":"2023","unstructured":"Shunxi W, Xiaoxue Y, Guanbin S, Li Y, Junyu J, Wanqian L. Serine metabolic reprogramming in tumorigenesis, tumor immunity, and clinical treatment. Adv Nutr. 2023;14(5):1050\u201366. https:\/\/doi.org\/10.1016\/j.advnut.2023.05.007.","journal-title":"Adv Nutr"},{"key":"2845_CR103","doi-asserted-by":"publisher","first-page":"4833","DOI":"10.2147\/OTT.S24643","volume":"13","author":"X Zhao","year":"2020","unstructured":"Zhao X, Fu J, Tang W, Yu L, Xu W. Inhibition of serine metabolism promotes resistance to cisplatin in gastric cancer. Onco Targets Ther. 2020;13:4833\u201342. https:\/\/doi.org\/10.2147\/OTT.S24643.","journal-title":"Onco Targets Ther"},{"issue":"1","key":"2845_CR104","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/1541-7786.MCR-19-0239","volume":"18","author":"DJM Nguyen","year":"2020","unstructured":"Nguyen DJM, Theodoropoulos G, Li YY, Wu C, Sha W, Feun LG, et al. Targeting the kynurenine pathway for the treatment of cisplatin-resistant lung cancer. Mol Cancer Res. 2020;18(1):105\u201317. https:\/\/doi.org\/10.1158\/1541-7786.MCR-19-0239.","journal-title":"Mol Cancer Res"},{"issue":"19","key":"2845_CR105","doi-asserted-by":"publisher","first-page":"12002","DOI":"10.3390\/ijms231912002","volume":"23","author":"H Wang","year":"2022","unstructured":"Wang H, Luo Y, Ran R, Li X, Ling H, Wen F, et al. IDO1 modulates the sensitivity of epithelial ovarian cancer cells to cisplatin through ROS\/p53-dependent apoptosis. Int J Mol Sci. 2022;23(19):12002. https:\/\/doi.org\/10.3390\/ijms231912002.","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2845_CR106","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10637-020-00924-3","volume":"38","author":"N Okano","year":"2020","unstructured":"Okano N, Naruge D, Kawai K, Kobayashi T, Nagashima F, Endou H, et al. First-in-human phase I study of JPH203, an L-type amino acid transporter 1 inhibitor, in patients with advanced solid tumors. Invest New Drugs. 2020;38(5):1495\u2013506. https:\/\/doi.org\/10.1007\/s10637-020-00924-3.","journal-title":"Invest New Drugs"},{"issue":"4","key":"2845_CR107","doi-asserted-by":"publisher","first-page":"101753","DOI":"10.1016\/j.jbc.2022.101753","volume":"298","author":"Q Li","year":"2022","unstructured":"Li Q, Zhong X, Yao W, Yu J, Wang C, Li Z, et al. Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. J Biol Chem. 2022;298(4):101753. https:\/\/doi.org\/10.1016\/j.jbc.2022.101753.","journal-title":"J Biol Chem"},{"issue":"20","key":"2845_CR108","doi-asserted-by":"publisher","first-page":"5082","DOI":"10.3390\/cancers15205082","volume":"15","author":"XD Lyu","year":"2023","unstructured":"Lyu XD, Liu Y, Wang J, Wei YC, Han Y, Li X, et al. A novel ASCT2 inhibitor, C118P, blocks glutamine transport and exhibits antitumour efficacy in breast cancer. Cancers (Basel). 2023;15(20):5082. https:\/\/doi.org\/10.3390\/cancers15205082.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"2845_CR109","doi-asserted-by":"publisher","first-page":"104536","DOI":"10.1016\/j.esmoop.2025.104536","volume":"10","author":"MA Gouda","year":"2025","unstructured":"Gouda MA, Voss MH, Tawbi H, Gordon M, Tykodi SS, Lam ET, et al. A phase I\/II study of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small cell lung cancer. ESMO Open. 2025;10(5):104536. https:\/\/doi.org\/10.1016\/j.esmoop.2025.104536.","journal-title":"ESMO Open"},{"issue":"15 Suppl","key":"2845_CR110","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1200\/JCO.2021.39.15_suppl.3001","volume":"39","author":"TA Yap","year":"2021","unstructured":"Yap TA, Dumbrava EE, Rodon Ahnert J, Hong DS, Pant S, Karp DD, et al. First-in-human biomarker-driven phase I trial of the selective glutaminase-1 inhibitor IACS-6274 in patients with molecularly selected advanced solid tumors. J Clin Oncol. 2021;39(15 Suppl):3001. https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.3001.","journal-title":"J Clin Oncol"},{"key":"2845_CR111","doi-asserted-by":"publisher","unstructured":"Novotna K, Tenora L, Slusher BS, Rais R. Therapeutic resurgence of 6-diazo-5-oxo-l-norleucine (DON) through tissue-targeted prodrugs. In: Slusher BS, Peters DE, editors. Adv Pharmacol. 2024;157\u2013180. https:\/\/doi.org\/10.1016\/bs.apha.2024.04.003.","DOI":"10.1016\/bs.apha.2024.04.003"},{"issue":"3","key":"2845_CR112","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s00280-008-0894-4","volume":"64","author":"J Guan","year":"2009","unstructured":"Guan J, Lo M, Dockery P, Mahon S, Karp CM, Buckley AR, et al. The xc\u2013 cystine\/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: use of sulfasalazine. Cancer Chemother Pharmacol. 2009;64(3):463\u201372. https:\/\/doi.org\/10.1007\/s00280-008-0894-4.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2845_CR113","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.addr.2020.07.013","volume":"159","author":"LM Butler","year":"2020","unstructured":"Butler LM, Perone Y, Dehairs J, Lupien LE, de Laat V, Talebi A, et al. Lipids and cancer: emerging roles in pathogenesis, diagnosis and therapeutic intervention. Adv Drug Deliv Rev. 2020;159:245\u201393. https:\/\/doi.org\/10.1016\/j.addr.2020.07.013.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"2845_CR114","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1038\/s41416-019-0650-z","volume":"122","author":"N Koundouros","year":"2020","unstructured":"Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in cancer. Br J Cancer. 2020;122(1):4\u201322. https:\/\/doi.org\/10.1038\/s41416-019-0650-z.","journal-title":"Br J Cancer"},{"issue":"9","key":"2845_CR115","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/nchembio.1603","volume":"10","author":"MA Hardwicke","year":"2014","unstructured":"Hardwicke MA, Rendina AR, Williams SP, Moore ML, Wang L, Krueger JA, et al. A human fatty acid synthase inhibitor binds beta-ketoacyl reductase in the keto-substrate site. Nat Chem Biol. 2014;10(9):774\u20139. https:\/\/doi.org\/10.1038\/nchembio.1603.","journal-title":"Nat Chem Biol"},{"issue":"13","key":"2845_CR116","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1158\/1078-0432.CCR-22-2807","volume":"29","author":"W Kelly","year":"2023","unstructured":"Kelly W, Diaz Duque AE, Michalek J, Konkel B, Caflisch L, Chen Y, et al. Phase II investigation of TVB-2640 (denifanstat) with bevacizumab in patients with first relapse high-grade astrocytoma. Clin Cancer Res. 2023;29(13):2419\u201325. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2807.","journal-title":"Clin Cancer Res"},{"issue":"16 Suppl","key":"2845_CR117","doi-asserted-by":"publisher","first-page":"e20609","DOI":"10.1200\/JCO.2022.40.16_suppl.e20609","volume":"40","author":"R Perets","year":"2022","unstructured":"Perets R, Geva R, McKean M, Goutopoulos A, Erez O, Phadnis M, et al. Phase 1 first-in-human trial of MTB-9655, an oral inhibitor of ACSS2, in patients with advanced solid tumors. J Clin Oncol. 2022;40(16 Suppl):e20609. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.e20609.","journal-title":"J Clin Oncol"},{"key":"2845_CR118","doi-asserted-by":"publisher","first-page":"105010","DOI":"10.1016\/j.ejps.2019.105010","volume":"137","author":"EQ Li","year":"2019","unstructured":"Li EQ, Zhao W, Zhang C, Qin LZ, Liu SJ, Feng ZQ, et al. Synthesis and anticancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors. Eur J Pharm Sci. 2019;137:105010. https:\/\/doi.org\/10.1016\/j.ejps.2019.105010.","journal-title":"Eur J Pharm Sci"},{"issue":"28","key":"2845_CR119","doi-asserted-by":"publisher","first-page":"19772","DOI":"10.1074\/jbc.M601140200","volume":"281","author":"M Smolle","year":"2006","unstructured":"Smolle M, Prior AE, Brown AE, Cooper A, Byron O, Lindsay JG. A new level of architectural complexity in the human pyruvate dehydrogenase complex. J Biol Chem. 2006;281(28):19772\u201380. https:\/\/doi.org\/10.1074\/jbc.M601140200.","journal-title":"J Biol Chem"},{"issue":"10","key":"2845_CR120","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1158\/1535-7163.MCT-19-0079","volume":"18","author":"BL Woolbright","year":"2019","unstructured":"Woolbright BL, Rajendran G, Harris RA, Taylor JA III. Metabolic flexibility in cancer: targeting the pyruvate dehydrogenase kinase-pyruvate dehydrogenase axis. Mol Cancer Ther. 2019;18(10):1673\u201381. https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0079.","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"2845_CR121","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.radonc.2009.06.025","volume":"92","author":"O Feron","year":"2009","unstructured":"Feron O. Pyruvate into lactate and back: from the Warburg effect to symbiotic energy fuel exchange in cancer cells. Radiother Oncol. 2009;92(3):329\u201333. https:\/\/doi.org\/10.1016\/j.radonc.2009.06.025.","journal-title":"Radiother Oncol"},{"issue":"12","key":"2845_CR122","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1021\/bi00605a017","volume":"17","author":"SJ Yeaman","year":"1978","unstructured":"Yeaman SJ, Hutcheson ET, Roche TE, Pettit FH, Brown JR, Reed LJ, et al. Sites of phosphorylation on pyruvate dehydrogenase from bovine kidney and heart. Biochemistry. 1978;17(12):2364\u201370. https:\/\/doi.org\/10.1021\/bi00605a017.","journal-title":"Biochemistry"},{"issue":"6","key":"2845_CR123","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.molcel.2011.10.015","volume":"44","author":"T Hitosugi","year":"2011","unstructured":"Hitosugi T, Fan J, Chung TW, Lythgoe K, Wang X, Xie J, et al. Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolism. Mol Cell. 2011;44(6):864\u201377. https:\/\/doi.org\/10.1016\/j.molcel.2011.10.015.","journal-title":"Mol Cell"},{"issue":"5","key":"2845_CR124","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1007\/s00345-012-0874-5","volume":"31","author":"D Baumunk","year":"2013","unstructured":"Baumunk D, Reichelt U, Hildebrandt J, Krause H, Ebbing J, Cash H, et al. Expression parameters of pyruvate dehydrogenase kinase-1 (PDK1) and DJ-1\/PARK7 in renal cell carcinoma. World J Urol. 2013;31(5):1191\u20136. https:\/\/doi.org\/10.1007\/s00345-012-0874-5.","journal-title":"World J Urol"},{"issue":"3","key":"2845_CR125","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.cmet.2006.02.002","volume":"3","author":"JW Kim","year":"2006","unstructured":"Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177\u201385. https:\/\/doi.org\/10.1016\/j.cmet.2006.02.002.","journal-title":"Cell Metab"},{"key":"2845_CR126","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.omtn.2020.08.037","volume":"23","author":"Y Li","year":"2021","unstructured":"Li Y, Zhang Y, Zhang S, Huang D, Li B, Liang G, et al. circARNT2 suppresses sensitivity of hepatocellular carcinoma cells to cisplatin via the miR-155-5p\/PDK1 axis. Mol Ther Nucleic Acids. 2021;23:244\u201354. https:\/\/doi.org\/10.1016\/j.omtn.2020.08.037.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"1","key":"2845_CR127","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1038\/s41419-025-07903-7","volume":"16","author":"K Tokumura","year":"2025","unstructured":"Tokumura K, Fukasawa K, Ichikawa J, Sadamori K, Hiraiwa M, Hinoi E. PDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3. Cell Death Dis. 2025;16(1):574. https:\/\/doi.org\/10.1038\/s41419-025-07903-7.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2845_CR128","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41389-020-0209-0","volume":"9","author":"MKY Siu","year":"2020","unstructured":"Siu MKY, Jiang YX, Wang JJ, Leung THY, Ngu SF, Cheung ANY, et al. PDK1 promotes ovarian cancer metastasis via \u03b15\u03b21 integrin and JNK\/IL-8 signaling. Oncogenesis. 2020;9(2):24. https:\/\/doi.org\/10.1038\/s41389-020-0209-0.","journal-title":"Oncogenesis"},{"issue":"5","key":"2845_CR129","doi-asserted-by":"publisher","first-page":"6361","DOI":"10.1002\/jcp.27369","volume":"234","author":"M Zhang","year":"2019","unstructured":"Zhang M, Cong Q, Zhang XY, Zhang MX, Lu YY, Xu CJ. Pyruvate dehydrogenase kinase 1 contributes to cisplatin resistance of ovarian cancer through EGFR activation. J Cell Physiol. 2019;234(5):6361\u201370. https:\/\/doi.org\/10.1002\/jcp.27369.","journal-title":"J Cell Physiol"},{"issue":"1","key":"2845_CR130","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41389-020-00299-3","volume":"10","author":"CR Huang","year":"2021","unstructured":"Huang CR, Chang TW, Lee CT, Shen CJ, Chang WC, Chen BK. ARNT deficiency represses pyruvate dehydrogenase kinase 1 to trigger ROS production and melanoma metastasis. Oncogenesis. 2021;10(1):11. https:\/\/doi.org\/10.1038\/s41389-020-00299-3.","journal-title":"Oncogenesis"},{"issue":"4","key":"2845_CR131","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1124\/mol.113.087197","volume":"84","author":"YY Chan","year":"2013","unstructured":"Chan YY, Kalpana S, Chang WC, Chen BK. Expression of aryl hydrocarbon receptor nuclear translocator enhances cisplatin resistance by upregulating MDR1 expression. Mol Pharmacol. 2013;84(4):591\u2013602. https:\/\/doi.org\/10.1124\/mol.113.087197.","journal-title":"Mol Pharmacol"},{"issue":"2","key":"2845_CR132","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ccell.2016.07.004","volume":"30","author":"YC Chae","year":"2016","unstructured":"Chae YC, Vaira V, Caino MC, Tang HY, Seo JH, Kossenkov AV, et al. Mitochondrial Akt regulation of hypoxic tumor reprogramming. Cancer Cell. 2016;30(2):257\u201372. https:\/\/doi.org\/10.1016\/j.ccell.2016.07.004.","journal-title":"Cancer Cell"},{"issue":"5","key":"2845_CR133","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.3390\/ijms22052537","volume":"22","author":"Y Li","year":"2021","unstructured":"Li Y, Kang J, Fu J, Luo H, Liu Y, Li Y, et al. PGC1\u03b1 promotes cisplatin resistance in ovarian cancer by regulating the HSP70\/HK2\/VDAC1 pathway. Int J Mol Sci. 2021;22(5):2537. https:\/\/doi.org\/10.3390\/ijms22052537.","journal-title":"Int J Mol Sci"},{"issue":"6","key":"2845_CR134","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1159\/000537819","volume":"109","author":"H Li","year":"2024","unstructured":"Li H, Sun J, Hu H, Wang Y. Transcription factor E2F8 activates PDK1-mediated DNA damage repair to enhance cisplatin resistance in lung adenocarcinoma. Pharmacology. 2024;109(6):341\u201356. https:\/\/doi.org\/10.1159\/000537819.","journal-title":"Pharmacology"},{"issue":"2","key":"2845_CR135","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1158\/0008-5472.CAN-11-1215","volume":"72","author":"T Contractor","year":"2012","unstructured":"Contractor T, Harris CR. p53 negatively regulates transcription of pyruvate dehydrogenase kinase PDK2. Cancer Res. 2012;72(2):560\u20137. https:\/\/doi.org\/10.1158\/0008-5472.CAN-11-1215.","journal-title":"Cancer Res"},{"issue":"11","key":"2845_CR136","doi-asserted-by":"publisher","first-page":"4627","DOI":"10.1111\/cas.15125","volume":"112","author":"S Kitamura","year":"2021","unstructured":"Kitamura S, Yamaguchi K, Murakami R, Furutake Y, Higasa K, Abiko K, et al. PDK2 leads to cisplatin resistance through suppression of mitochondrial function in ovarian clear cell carcinoma. Cancer Sci. 2021;112(11):4627\u201340. https:\/\/doi.org\/10.1111\/cas.15125.","journal-title":"Cancer Sci"},{"issue":"1","key":"2845_CR137","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.canlet.2015.11.023","volume":"371","author":"JL Roh","year":"2016","unstructured":"Roh JL, Park JY, Kim EH, Jang HJ, Kwon M. Activation of mitochondrial oxidation by PDK2 inhibition reverses cisplatin resistance in head and neck cancer. Cancer Lett. 2016;371(1):20\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2015.11.023.","journal-title":"Cancer Lett"},{"issue":"2","key":"2845_CR138","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1158\/1078-0432.CCR-08-0930","volume":"15","author":"W Sun","year":"2009","unstructured":"Sun W, Zhou S, Chang SS, McFate T, Verma A, Califano JA. Mitochondrial mutations contribute to HIF1\u03b1 accumulation via increased ROS and upregulated PDK2 in head and neck squamous cell carcinoma. Clin Cancer Res. 2009;15(2):476\u201384. https:\/\/doi.org\/10.1158\/1078-0432.CCR-08-0930.","journal-title":"Clin Cancer Res"},{"key":"2845_CR139","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40170-022-00300-0","volume":"10","author":"WH Sun","year":"2022","unstructured":"Sun WH, Chen YH, Lee HH, Tang YW, Sun KH. PDK1- and PDK2-mediated metabolic reprogramming contributes to TGF\u03b21-promoted stem-like properties in head and neck cancer. Cancer Metab. 2022;10:23. https:\/\/doi.org\/10.1186\/s40170-022-00300-0.","journal-title":"Cancer Metab"},{"issue":"21","key":"2845_CR140","doi-asserted-by":"publisher","first-page":"15773","DOI":"10.1074\/jbc.M909488199","volume":"275","author":"JC Baker","year":"2000","unstructured":"Baker JC, Yan X, Peng T, Kasten S, Roche TE. Marked differences between two isoforms of human pyruvate dehydrogenase kinase. J Biol Chem. 2000;275(21):15773\u201381. https:\/\/doi.org\/10.1074\/jbc.M909488199.","journal-title":"J Biol Chem"},{"issue":"42","key":"2845_CR141","doi-asserted-by":"publisher","first-page":"28106","DOI":"10.1074\/jbc.M803508200","volume":"283","author":"CW Lu","year":"2008","unstructured":"Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by HIF-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008;283(42):28106\u201314. https:\/\/doi.org\/10.1074\/jbc.M803508200.","journal-title":"J Biol Chem"},{"issue":"10","key":"2845_CR142","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.7150\/thno.31301","volume":"9","author":"J Xu","year":"2019","unstructured":"Xu J, Shi Q, Xu W, Zhou Q, Shi R, Ma Y, et al. Metabolic enzyme PDK3 forms a positive feedback loop with HSF1 to drive chemoresistance. Theranostics. 2019;9(10):2999\u20133015. https:\/\/doi.org\/10.7150\/thno.31301.","journal-title":"Theranostics"},{"issue":"11","key":"2845_CR143","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1016\/j.celrep.2016.08.018","volume":"16","author":"LY Wang","year":"2016","unstructured":"Wang LY, Hung CL, Chen YR, Yang JC, Wang J, Campbell M, et al. KDM4A coactivates E2F1 to regulate the PDK-dependent metabolic switch between mitochondrial oxidation and glycolysis. Cell Rep. 2016;16(11):3016\u201327. https:\/\/doi.org\/10.1016\/j.celrep.2016.08.018.","journal-title":"Cell Rep"},{"issue":"9","key":"2845_CR144","doi-asserted-by":"publisher","first-page":"BSR20190654","DOI":"10.1042\/BSR20190654","volume":"39","author":"L Feng","year":"2019","unstructured":"Feng L, Cheng K, Zang R, Wang Q, Wang J. miR-497-5p inhibits gastric cancer cell proliferation through targeting PDK3. Biosci Rep. 2019;39(9):BSR20190654. https:\/\/doi.org\/10.1042\/BSR20190654.","journal-title":"Biosci Rep"},{"issue":"6","key":"2845_CR145","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1002\/1878-0261.13611","volume":"18","author":"S Srinath","year":"2024","unstructured":"Srinath S, Jishnu PV, Varghese VK, Shukla V, Adiga D, Mallya S, et al. Regulation and tumor-suppressive function of the miR-379\/miR-656 (C14MC) cluster in cervical cancer. Mol Oncol. 2024;18(6):1608. https:\/\/doi.org\/10.1002\/1878-0261.13611.","journal-title":"Mol Oncol"},{"issue":"9","key":"2845_CR146","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1158\/1535-7163.MCT-18-0063","volume":"17","author":"BL Woolbright","year":"2018","unstructured":"Woolbright BL, Choudhary D, Mikhalyuk A, Trammel C, Shanmugam S, Abbott E, et al. The role of pyruvate dehydrogenase kinase-4 (PDK4) in bladder cancer and chemoresistance. Mol Cancer Ther. 2018;17(9):2004\u201312. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-0063.","journal-title":"Mol Cancer Ther"},{"issue":"2","key":"2845_CR147","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s00280-020-04188-9","volume":"87","author":"S Yu","year":"2021","unstructured":"Yu S, Li Y, Ren H, Zhou H, Ning Q, Chen X, et al. PDK4 promotes tumorigenesis and cisplatin resistance in lung adenocarcinoma via EPAS1 regulation. Cancer Chemother Pharmacol. 2021;87(2):207\u201315. https:\/\/doi.org\/10.1007\/s00280-020-04188-9.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"2845_CR148","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/2049-3002-2-20","volume":"2","author":"Y Sun","year":"2014","unstructured":"Sun Y, Daemen A, Hatzivassiliou G, Arnott D, Wilson C, Zhuang G, et al. Metabolic and transcriptional profiling reveals PDK4 as a mediator of epithelial\u2013mesenchymal transition and drug resistance. Cancer Metab. 2014;2(1):20. https:\/\/doi.org\/10.1186\/2049-3002-2-20.","journal-title":"Cancer Metab"},{"issue":"4","key":"2845_CR149","doi-asserted-by":"publisher","first-page":"918","DOI":"10.7150\/jca.27226","volume":"10","author":"C Yang","year":"2019","unstructured":"Yang C, Wang S, Ruan H, Li B, Cheng Z, He J, et al. Downregulation of PDK4 increases lipogenesis and associates with poor prognosis in hepatocellular carcinoma. J Cancer. 2019;10(4):918\u201326. https:\/\/doi.org\/10.7150\/jca.27226.","journal-title":"J Cancer"},{"issue":"4","key":"2845_CR150","doi-asserted-by":"publisher","first-page":"e99247","DOI":"10.15252\/msb.20199247","volume":"16","author":"M Oberhuber","year":"2020","unstructured":"Oberhuber M, Pecoraro M, Rusz M, Oberhuber G, Wieselberg M, Haslinger P, et al. STAT3-dependent analysis reveals PDK4 as independent predictor of recurrence in prostate cancer. Mol Syst Biol. 2020;16(4):e99247. https:\/\/doi.org\/10.15252\/msb.20199247.","journal-title":"Mol Syst Biol"},{"issue":"43","key":"2845_CR151","doi-asserted-by":"publisher","first-page":"29739","DOI":"10.1074\/jbc.M114.584821","volume":"289","author":"Z Liu","year":"2014","unstructured":"Liu Z, Chen X, Wang Y, Peng H, Wang Y, Jing Y, et al. PDK4 protein promotes tumorigenesis through activation of cAMP-response element-binding protein (CREB)-Ras homolog enriched in brain (RHEB)-mTORC1 signaling cascade. J Biol Chem. 2014;289(43):29739\u201349. https:\/\/doi.org\/10.1074\/jbc.M114.584821.","journal-title":"J Biol Chem"},{"issue":"3","key":"2845_CR152","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1093\/nar\/gkv026","volume":"43","author":"MY Kim","year":"2015","unstructured":"Kim MY, Koh DI, Choi WI, Jeon BN, Jeong DY, Kim KS, et al. ZBTB2 increases PDK4 expression by transcriptional repression of RelA\/p65. Nucleic Acids Res. 2015;43(3):1609\u201325. https:\/\/doi.org\/10.1093\/nar\/gkv026.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2845_CR153","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/bjc.2017.38","volume":"116","author":"D Leclerc","year":"2017","unstructured":"Leclerc D, Pham DNT, L\u00e9vesque N, Truongcao M, Foulkes WD, Sapienza C, et al. Oncogenic role of PDK4 in human colon cancer cells. Br J Cancer. 2017;116(7):930\u20136. https:\/\/doi.org\/10.1038\/bjc.2017.38.","journal-title":"Br J Cancer"},{"issue":"44","key":"2845_CR154","doi-asserted-by":"publisher","first-page":"6164","DOI":"10.1038\/onc.2017.224","volume":"36","author":"AG Trinidad","year":"2017","unstructured":"Trinidad AG, Whalley N, Rowlinson R, Delpuech O, Dudley P, Rooney C, et al. Pyruvate dehydrogenase kinase 4 exhibits a novel role in the activation of mutant KRAS, regulating cell growth in lung and colorectal tumor cells. Oncogene. 2017;36(44):6164\u201376. https:\/\/doi.org\/10.1038\/onc.2017.224.","journal-title":"Oncogene"},{"issue":"24","key":"2845_CR155","doi-asserted-by":"publisher","first-page":"7430","DOI":"10.1158\/0008-5472.CAN-14-1439","volume":"74","author":"S Tao","year":"2014","unstructured":"Tao S, Wang S, Moghaddam SJ, Ooi A, Chapman E, Wong PK, et al. Oncogenic KRAS confers chemoresistance by upregulating NRF2. Cancer Res. 2014;74(24):7430\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1439.","journal-title":"Cancer Res"},{"issue":"7","key":"2845_CR156","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/onc.2016.265","volume":"36","author":"G Li","year":"2017","unstructured":"Li G, Li M, Hu J, Lei R, Xiong H, Ji H, et al. The microRNA-182-PDK4 axis regulates lung tumorigenesis by modulating pyruvate dehydrogenase and lipogenesis. Oncogene. 2017;36(7):989\u201398. https:\/\/doi.org\/10.1038\/onc.2016.265.","journal-title":"Oncogene"},{"issue":"24","key":"2845_CR157","doi-asserted-by":"publisher","first-page":"12862","DOI":"10.18632\/oncotarget.2656","volume":"5","author":"JD Moore","year":"2014","unstructured":"Moore JD, Staniszewska A, Shaw T, D\u2019Alessandro J, Davis B, Surgenor A, et al. VER-246608, a novel panisoform ATP competitive inhibitor of pyruvate dehydrogenase kinase, disrupts Warburg metabolism and induces context-dependent cytostasis in cancer cells. Oncotarget. 2014;5(24):12862\u201376. https:\/\/doi.org\/10.18632\/oncotarget.2656.","journal-title":"Oncotarget"},{"issue":"6","key":"2845_CR158","doi-asserted-by":"publisher","first-page":"R1487","DOI":"10.1152\/ajpregu.00498.2010","volume":"300","author":"EC Dunford","year":"2011","unstructured":"Dunford EC, Herbst EA, Jeoung NH, Gittings W, Greig Inglis J, Vandenboom R, et al. PDH activation during in vitro muscle contractions in PDH kinase 2 knockout mice: effect of PDH kinase 1 compensation. Am J Physiol Regul Integr Comp Physiol. 2011;300(6):R1487\u201393. https:\/\/doi.org\/10.1152\/ajpregu.00498.2010.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"3","key":"2845_CR159","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10637-022-01235-5","volume":"40","author":"SF Powell","year":"2022","unstructured":"Powell SF, Mazurczak M, Dib EG, Bleeker JS, Geeraerts LH, Tinguely M, et al. Phase II study of dichloroacetate in combination with chemoradiotherapy for unresected, locally advanced head and neck squamous cell carcinoma. Invest New Drugs. 2022;40(3):622\u201333. https:\/\/doi.org\/10.1007\/s10637-022-01235-5.","journal-title":"Invest New Drugs"},{"issue":"10","key":"2845_CR160","doi-asserted-by":"publisher","first-page":"336","DOI":"10.12998\/wjcc.v4.i10.336","volume":"4","author":"A Khan","year":"2016","unstructured":"Khan A, Andrews D, Blackburn AC. Long-term stabilization of stage 4 colon cancer using sodium dichloroacetate therapy. World J Clin Cases. 2016;4(10):336\u201343. https:\/\/doi.org\/10.12998\/wjcc.v4.i10.336.","journal-title":"World J Clin Cases"},{"issue":"1","key":"2845_CR161","doi-asserted-by":"publisher","first-page":"341","DOI":"10.21873\/invivo.12265","volume":"35","author":"L Korsakova","year":"2021","unstructured":"Korsakova L, Krasko JA, Stankevicius E. Metabolic-targeted combination therapy with dichloroacetate and metformin suppresses glioblastoma cell line growth in vitro and in vivo. Vivo. 2021;35(1):341\u20138. https:\/\/doi.org\/10.21873\/invivo.12265.","journal-title":"Vivo"},{"issue":"9","key":"2845_CR162","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1097\/NEN.0b013e3181b40217","volume":"68","author":"NA Calcutt","year":"2009","unstructured":"Calcutt NA, Lopez VL, Bautista AD, Mizisin LM, Torres BR, Shroads AL, et al. Peripheral neuropathy in rats exposed to dichloroacetate. J Neuropathol Exp Neurol. 2009;68(9):985\u201393. https:\/\/doi.org\/10.1097\/NEN.0b013e3181b40217.","journal-title":"J Neuropathol Exp Neurol"},{"issue":"5","key":"2845_CR163","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2337\/diabetes.49.5.775","volume":"49","author":"MJ Holness","year":"2000","unstructured":"Holness MJ, Kraus A, Harris RA, Sugden MC. Targeted upregulation of pyruvate dehydrogenase kinase-4 in slow-twitch skeletal muscle underlies the stable modification of regulatory characteristics induced by high-fat feeding. Diabetes. 2000;49(5):775\u201381. https:\/\/doi.org\/10.2337\/diabetes.49.5.775.","journal-title":"Diabetes"},{"issue":"6","key":"2845_CR164","doi-asserted-by":"publisher","first-page":"302","DOI":"10.4161\/isl.3.6.17806","volume":"3","author":"MC Sugden","year":"2011","unstructured":"Sugden MC, Holness MJ. The pyruvate carboxylase-pyruvate dehydrogenase axis in islet pyruvate metabolism. Islets. 2011;3(6):302\u201319. https:\/\/doi.org\/10.4161\/isl.3.6.17806.","journal-title":"Islets"},{"issue":"4","key":"2845_CR165","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1002\/jcp.27224","volume":"234","author":"A Muscella","year":"2019","unstructured":"Muscella A, Cossa LG, Vetrugno C, Antonaci G, Marsigliante S. ADP sensitizes ZL55 cells to the activity of cisplatin. J Cell Physiol. 2019;234(4):4409\u201317. https:\/\/doi.org\/10.1002\/jcp.27224.","journal-title":"J Cell Physiol"},{"issue":"42","key":"2845_CR166","doi-asserted-by":"publisher","first-page":"13442","DOI":"10.1021\/bi0494875","volume":"43","author":"H Bao","year":"2004","unstructured":"Bao H, Kasten SA, Yan X, Hiromasa Y, Roche TE. Pyruvate dehydrogenase kinase isoform 2 activity stimulated by speeding up the rate of dissociation of ADP. Biochemistry. 2004;43(42):13442\u201351. https:\/\/doi.org\/10.1021\/bi0494875.","journal-title":"Biochemistry"},{"issue":"4","key":"2845_CR167","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1002\/ijc.29564","volume":"138","author":"E Saunier","year":"2016","unstructured":"Saunier E, Benelli C, Bortoli S. The pyruvate dehydrogenase complex in cancer: an old metabolic gatekeeper regulated by new pathways and pharmacological agents. Int J Cancer. 2016;138(4):809\u201317. https:\/\/doi.org\/10.1002\/ijc.29564.","journal-title":"Int J Cancer"},{"issue":"1","key":"2845_CR168","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1038\/s41420-024-02006-2","volume":"10","author":"R Su","year":"2024","unstructured":"Su R, Shao Y, Huang M, Liu D, Yu H, Qiu Y. Immunometabolism in cancer: basic mechanisms and new targeting strategy. Cell Death Discov. 2024;10(1):236. https:\/\/doi.org\/10.1038\/s41420-024-02006-2.","journal-title":"Cell Death Discov"},{"issue":"7","key":"2845_CR169","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1093\/cvr\/cvad038","volume":"119","author":"MJ Forteza","year":"2023","unstructured":"Forteza MJ, Berg M, Edsfeldt A, Sun J, Baumgartner R, Kareinen I, et al. Pyruvate dehydrogenase kinase regulates vascular inflammation in atherosclerosis and increases cardiovascular risk. Cardiovasc Res. 2023;119(7):1524\u201336. https:\/\/doi.org\/10.1093\/cvr\/cvad038.","journal-title":"Cardiovasc Res"},{"issue":"1","key":"2845_CR170","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.1038\/s41598-023-34087-x","volume":"13","author":"CE Nunes-Xavier","year":"2023","unstructured":"Nunes-Xavier CE, Emaldi M, Mingo J, Oyjord T, Maelandsmo GM, Fodstad O, et al. Expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma. Sci Rep. 2023;13(1):7339. https:\/\/doi.org\/10.1038\/s41598-023-34087-x.","journal-title":"Sci Rep"},{"issue":"6","key":"2845_CR171","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"CH Chang","year":"2015","unstructured":"Chang CH, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162(6):1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"issue":"1","key":"2845_CR172","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1038\/s41419-025-07482-7","volume":"16","author":"CH Ding","year":"2025","unstructured":"Ding CH, Yan FZ, Xu BN, Qian H, Hong XL, Liu SQ, et al. PRMT3 drives PD-L1-mediated immune escape through activating PDHK1-regulated glycolysis in hepatocellular carcinoma. Cell Death Dis. 2025;16(1):158. https:\/\/doi.org\/10.1038\/s41419-025-07482-7.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2845_CR173","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1038\/s41590-024-01999-3","volume":"25","author":"RM Peralta","year":"2024","unstructured":"Peralta RM, Xie B, Lontos K, Nieves-Rosado H, Spahr K, Joshi S, et al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. 2024;25(12):2297\u2013307. https:\/\/doi.org\/10.1038\/s41590-024-01999-3.","journal-title":"Nat Immunol"},{"issue":"5","key":"2845_CR174","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cmet.2016.08.011","volume":"24","author":"A Brand","year":"2016","unstructured":"Brand A, Singer K, Koehl GE, Kolitzus M, Schoenhammer G, Thiel A, et al. LDHA-associated lactic acid production blunts tumor immunosurveillance by T and NK cells. Cell Metab. 2016;24(5):657\u201371. https:\/\/doi.org\/10.1016\/j.cmet.2016.08.011.","journal-title":"Cell Metab"},{"issue":"7519","key":"2845_CR175","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1038\/nature13490","volume":"513","author":"OR Colegio","year":"2014","unstructured":"Colegio OR, Chu NQ, Szabo AL, Chu T, Rhebergen AM, Jairam V, et al. Functional polarization of tumor-associated macrophages by tumor-derived lactic acid. Nature. 2014;513(7519):559\u201363. https:\/\/doi.org\/10.1038\/nature13490.","journal-title":"Nature"},{"issue":"3","key":"2845_CR176","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.immuni.2025.02.008","volume":"58","author":"A Llibre","year":"2025","unstructured":"Llibre A, Kucuk S, Gope A, Certo M, Mauro C. Lactate: a key regulator of the immune response. Immunity. 2025;58(3):535\u201354. https:\/\/doi.org\/10.1016\/j.immuni.2025.02.008.","journal-title":"Immunity"},{"issue":"11","key":"2845_CR177","doi-asserted-by":"publisher","first-page":"1659092","DOI":"10.1080\/2162402X.2019.1659092","volume":"8","author":"JJ Wang","year":"2019","unstructured":"Wang JJ, Siu MK, Jiang YX, Leung TH, Chan DW, Cheng RR, et al. Aberrant upregulation of PDK1 in ovarian cancer cells impairs CD8\u2009+\u2009T-cell function and survival through elevation of PD-L1. Oncoimmunology. 2019;8(11):1659092. https:\/\/doi.org\/10.1080\/2162402X.2019.1659092.","journal-title":"Oncoimmunology"},{"issue":"6","key":"2845_CR178","doi-asserted-by":"publisher","first-page":"3117","DOI":"10.62347\/QWKZ3078","volume":"14","author":"Z Liu","year":"2024","unstructured":"Liu Z. PDK3 drives colorectal carcinogenesis and immune evasion and is a therapeutic target for boosting immunotherapy. Am J Cancer Res. 2024;14(6):3117\u201329. https:\/\/doi.org\/10.62347\/QWKZ3078.","journal-title":"Am J Cancer Res"},{"key":"2845_CR179","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.canlet.2020.04.016","volume":"484","author":"L Eisenberg","year":"2020","unstructured":"Eisenberg L, Eisenberg-Bord M, Eisenberg-Lerner A, Sagi-Eisenberg R. Metabolic alterations in the tumor microenvironment and their role in oncogenesis. Cancer Lett. 2020;484:65\u201371. https:\/\/doi.org\/10.1016\/j.canlet.2020.04.016.","journal-title":"Cancer Lett"},{"issue":"14","key":"2845_CR180","doi-asserted-by":"publisher","first-page":"7265","DOI":"10.3390\/ijms22147265","volume":"22","author":"KM Cook","year":"2021","unstructured":"Cook KM, Shen H, McKelvey KJ, Gee HE, Hau E. Targeting glucose metabolism of cancer cells with dichloroacetate to radiosensitize high-grade gliomas. Int J Mol Sci. 2021;22(14):7265. https:\/\/doi.org\/10.3390\/ijms22147265.","journal-title":"Int J Mol Sci"},{"issue":"12","key":"2845_CR181","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1016\/j.str.2008.10.010","volume":"16","author":"M Kato","year":"2008","unstructured":"Kato M, Wynn RM, Chuang JL, Tso SC, Machius M, Li J, et al. Structural basis for inactivation of the human pyruvate dehydrogenase complex by phosphorylation. Structure. 2008;16(12):1849\u201359. https:\/\/doi.org\/10.1016\/j.str.2008.10.010.","journal-title":"Structure"},{"issue":"52","key":"2845_CR182","doi-asserted-by":"publisher","first-page":"22199","DOI":"10.1073\/pnas.0912276106","volume":"106","author":"S Dhar","year":"2009","unstructured":"Dhar S, Lippard SJ. Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate. Proc Natl Acad Sci U S A. 2009;106(52):22199\u2013204. https:\/\/doi.org\/10.1073\/pnas.0912276106.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2845_CR183","doi-asserted-by":"publisher","first-page":"409","DOI":"10.3892\/ijo.2010.851","volume":"38","author":"J Xie","year":"2011","unstructured":"Xie J, Wang BS, Yu DH, Lu Q, Ma J, Qi H, et al. Dichloroacetate shifts the metabolism from glycolysis to glucose oxidation and exhibits synergistic growth inhibition with cisplatin in HeLa cells. Int J Oncol. 2011;38(2):409\u201317. https:\/\/doi.org\/10.3892\/ijo.2010.851.","journal-title":"Int J Oncol"},{"issue":"5","key":"2845_CR184","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1021\/cb400944y","volume":"9","author":"RK Pathak","year":"2014","unstructured":"Pathak RK, Marrache S, Harn DA, Dhar S. Mito-DCA: a mitochondrion-targeted molecular scaffold for efficacious delivery of metabolic modulator dichloroacetate. ACS Chem Biol. 2014;9(5):1178\u201387. https:\/\/doi.org\/10.1021\/cb400944y.","journal-title":"ACS Chem Biol"},{"issue":"10","key":"2845_CR185","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1080\/10715760400004168","volume":"38","author":"LG Korotchkina","year":"2004","unstructured":"Korotchkina LG, Sidhu S, Patel MS. R-lipoic acid inhibits mammalian pyruvate dehydrogenase kinase. Free Radic Res. 2004;38(10):1083\u201392. https:\/\/doi.org\/10.1080\/10715760400004168.","journal-title":"Free Radic Res"},{"issue":"1","key":"2845_CR186","doi-asserted-by":"publisher","first-page":"101122","DOI":"10.1016\/j.adro.2022.101122","volume":"8","author":"HY Khan","year":"2022","unstructured":"Khan HY, Kamgar M, Aboukameel A, Bannoura S, Chung BY, Li Y, et al. Targeting cellular metabolism with CPI-613 sensitizes pancreatic cancer cells to radiation therapy. Adv Radiat Oncol. 2022;8(1):101122. https:\/\/doi.org\/10.1016\/j.adro.2022.101122.","journal-title":"Adv Radiat Oncol"},{"issue":"23","key":"2845_CR187","doi-asserted-by":"publisher","first-page":"2556","DOI":"10.1182\/blood.V126.23.2556.2556","volume":"126","author":"T Pardee","year":"2015","unstructured":"Pardee T, Pladna K, Isom S, Ellis LR, Berenzon D, Howard D, et al. The mitochondrial metabolism inhibitor CPI-613 in combination with high-dose Ara-C and mitoxantrone is highly active in poor-risk relapsed or refractory acute myeloid leukemia. Blood. 2015;126(23):2556. https:\/\/doi.org\/10.1182\/blood.V126.23.2556.2556.","journal-title":"Blood"},{"issue":"22","key":"2845_CR188","doi-asserted-by":"publisher","first-page":"4923","DOI":"10.1158\/0008-5472.CAN-15-1023","volume":"75","author":"W Sun","year":"2015","unstructured":"Sun W, Xie Z, Liu Y, Zhao D, Wu Z, Zhang D, et al. JX06 selectively inhibits pyruvate dehydrogenase kinase PDK1 by a covalent cysteine modification. Cancer Res. 2015;75(22):4923\u201336. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-1023.","journal-title":"Cancer Res"},{"issue":"6","key":"2845_CR189","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1042\/bst0311165","volume":"31","author":"RM Mayers","year":"2003","unstructured":"Mayers RM, Butlin RJ, Kilgour E, Leighton B, Martin D, Myatt J, et al. AZD7545, a novel inhibitor of pyruvate dehydrogenase kinase 2, activates pyruvate dehydrogenase in vivo and improves blood glucose control in obese Zucker rats. Biochem Soc Trans. 2003;31(6):1165\u20137. https:\/\/doi.org\/10.1042\/bst0311165.","journal-title":"Biochem Soc Trans"},{"issue":"2","key":"2845_CR190","doi-asserted-by":"publisher","first-page":"R102","DOI":"10.1152\/ajpregu.00150.2013","volume":"306","author":"EAF Herbst","year":"2014","unstructured":"Herbst EAF, MacPherson REK, LeBlanc PJ, Roy BD, Jeoung NH, Harris RA, et al. Pyruvate dehydrogenase kinase-4 contributes to the recirculation of gluconeogenic precursors during postexercise glycogen recovery. Am J Physiol Regul Integr Comp Physiol. 2014;306(2):R102\u20137. https:\/\/doi.org\/10.1152\/ajpregu.00150.2013.","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"4","key":"2845_CR191","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1152\/japplphysiol.00132.2004","volume":"97","author":"MJ Watt","year":"2004","unstructured":"Watt MJ, Heigenhauser GJF, LeBlanc PJ, Inglis JG, Spriet LL, Peters SJ. Rapid upregulation of pyruvate dehydrogenase kinase activity in human skeletal muscle during prolonged exercise. J Appl Physiol (1985). 2004;97(4):1261\u20137. https:\/\/doi.org\/10.1152\/japplphysiol.00132.2004.","journal-title":"J Appl Physiol (1985)"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-026-02845-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02845-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-026-02845-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T21:04:45Z","timestamp":1781643885000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12964-026-02845-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,28]]},"references-count":191,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2845"],"URL":"https:\/\/doi.org\/10.1186\/s12964-026-02845-9","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,28]]},"assertion":[{"value":"1 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have read and approved the final manuscript and consent to its submission to the journal.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}